Skip to main content
Current Level of Coverage

Current Level of Coverage

  • Globally, 3.1 billion rapid diagnostic tests (RDTs) for malaria were sold by manufacturers in 2010–2020, with nearly 81% of these sales being to sub-Saharan African countries. In the same period, national malaria programmes (NMPs) distributed 2.2 billion RDTs – 88% in sub-Saharan Africa.
  • National data reported by NMPs show that, in the same period, 2.1 billion artemisinin-based combination therapies (ACTs) were delivered to health service providers to treat malaria patients in the public health sector.

  • Manufacturers’ delivery data for 2004–2020 show that almost 2.3 billion insecticide-treated mosquito nets (ITNs) were supplied globally in that period, of which 2 billion (86%) were supplied to sub-Saharan Africa.
  • Manufacturers delivered about 229 million ITNs to malaria endemic countries in 2020. About 91% of these ITNs were delivered to countries in sub-Saharan Africa.

  • By 2020, 65% of households in sub-Saharan Africa had at least one ITN, increasing from about 5% in 2000. Subsequently, the percentage of the population sleeping under an ITN also increased considerably between 2000 and 2020, for the whole population (from 2% to 43%), for children aged under 5 years (from 3% to 49%) and for pregnant women (from 3% to 49%).
  • The number of children reached with at least one dose of seasonal malaria chemoprevention (SMC) steadily increased, from about 0.2 million in 2012 to about 33.5 million in 2020.